As of 2026-03-31, the Relative Valuation of Urogen Pharma Ltd (URGN) is (2.05) USD. This relative valuation is based on P/E multiples. With the latest stock price at 17.17 USD, the upside of Urogen Pharma Ltd based on Relative Valuation is -111.9%.
The range of the Relative Valuation is (1.77) - (12.68) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.6x - 5.2x | 0.7x |
| Forward P/E multiples | -0.6x - 4.0x | 0.6x |
| Fair Price | (1.77) - (12.68) | (2.05) |
| Upside | -110.3% - -173.8% | -111.9% |
| Date | P/E |
| 2026-03-20 | -5.59 |
| 2026-03-19 | -5.90 |
| 2026-03-18 | -5.86 |
| 2026-03-17 | -5.90 |
| 2026-03-16 | -5.94 |
| 2026-03-13 | -5.85 |
| 2026-03-12 | -5.96 |
| 2026-03-11 | -5.98 |
| 2026-03-10 | -6.17 |
| 2026-03-09 | -6.31 |
| 2026-03-06 | -6.49 |
| 2026-03-05 | -6.22 |
| 2026-03-04 | -6.39 |
| 2026-03-03 | -5.97 |
| 2026-03-02 | -6.03 |
| 2026-02-27 | -6.88 |
| 2026-02-26 | -6.72 |
| 2026-02-25 | -6.56 |
| 2026-02-24 | -6.58 |
| 2026-02-23 | -6.63 |
| 2026-02-20 | -6.68 |
| 2026-02-19 | -6.91 |
| 2026-02-18 | -7.06 |
| 2026-02-17 | -6.53 |
| 2026-02-13 | -6.37 |
| 2026-02-12 | -6.41 |
| 2026-02-11 | -6.70 |
| 2026-02-10 | -6.87 |
| 2026-02-09 | -6.95 |
| 2026-02-06 | -6.77 |
| 2026-02-05 | -6.51 |
| 2026-02-04 | -6.57 |
| 2026-02-03 | -6.34 |
| 2026-02-02 | -6.25 |
| 2026-01-30 | -6.22 |
| 2026-01-29 | -6.56 |
| 2026-01-28 | -6.76 |
| 2026-01-27 | -6.93 |
| 2026-01-26 | -6.69 |
| 2026-01-23 | -6.34 |
| 2026-01-22 | -6.34 |
| 2026-01-21 | -6.10 |
| 2026-01-20 | -6.13 |
| 2026-01-16 | -5.96 |
| 2026-01-15 | -6.20 |
| 2026-01-14 | -5.94 |
| 2026-01-13 | -6.29 |
| 2026-01-12 | -6.80 |
| 2026-01-09 | -6.74 |
| 2026-01-08 | -7.44 |